Intralesional Cryotherapy With a Argon Gas Based Device for the Treatment of Keloid and Hypertrophic Scars

Overview

This prospective evaluation studies the effectiveness of Intralesional (IL) cryotherapy with a argon gas based device in treating keloids and hypertrophic scars in population consisting of all Fitzpatrick skin type patients

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2012

Detailed Description

Intralesional (IL) cryotherapy is a novel treatment for keloids and hypertrophic scars, in which the scar is frozen from inside. Published results are promising, however only Caucasian patient populations have been studied. This prospective evaluation studies the effectiveness of IL cryotherapy in treating keloids and hypertrophic scars in a population consisting of all Fitzpatrick skin type patients. Multiple devices are available, mostly based on a simple open system. Closed, argon gas based, systems are highly controlled and provide accurate freezing. However, this technique has never been used for IL cryotherapy for the treatment of keloid or hypertrophic scars. All patients with keloid or hypertrophic scars meeting inclusion criteria were treated with a argon based device called Seednet. Scar quality and possible recurrence are assessed pre- and postsurgery (3, 6 and 12 months) with objective devices determine scar color, scar elasticity, scar volume and patient's skin type. In addition, scars are evaluated using the Patient and Observer Scar Assessment Scale.

Interventions

  • Procedure: Intralesional cryotherapy
    • Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle

Arms, Groups and Cohorts

  • Other: keloid or hypertrophic scars
    • All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy

Clinical Trial Outcome Measures

Primary Measures

  • Recurrence
    • Time Frame: 0-12 months
    • Judgment of recurrence, defined as a growing, pruritic, nodular scar

Secondary Measures

  • Scar elasticity
    • Time Frame: 0-12months
    • Scar elasticity, measured in two parameters: extension and elasticity

Participating in This Clinical Trial

Inclusion Criteria

  • Keloids, defined as excessive scar tissue raised above skin level and proliferating beyond the confines of the original lesion – Hypertrophic scars1 older than 12 months and insensitive to other treatments. Keloids were distinguished from hypertrophic scars based on the clinical judgment of experienced plastic surgeons and on the age of the scar (>1yr) – A period between previous treatment and IL cryotherapy covered a minimum of 12 weeks – Patients with all Fitzpatrick17 skin types – Patients older than 10 years of age Exclusion Criteria:

  • pregnancy – diabetes mellitus

Gender Eligibility: All

Minimum Age: 10 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Amsterdam UMC, location VUmc
  • Provider of Information About this Clinical Study
    • Principal Investigator: Michiel van Leeuwen, MD – Amsterdam UMC, location VUmc
  • Overall Official(s)
    • Michiel CE van Leeuwen, MD, Principal Investigator, VUmc

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.